Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares, rose in value on Friday, March 07, with the stock price down by -2.90% to the previous day’s close as strong demand from buyers drove the stock to $2.01.
Actively observing the price movement in the last trading, the stock closed the session at $2.07. Referring to stock’s 52-week performance, its high was $6.62, and the low was $1.68. On the whole, AUTL has fluctuated by -5.63% over the past month.
With the market capitalization of Autolus Therapeutics plc ADR currently standing at about $534.90 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 2.98M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AUTL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of AUTL currently trading nearly 4.63% and -6.06% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.39, while the 7-day volatility ratio is showing 7.87% which for the 30-day chart, stands at 6.07%. Furthermore, Autolus Therapeutics plc ADR (AUTL)’s beta value is 1.97, and its average true range (ATR) is 0.13.
A comparison of Autolus Therapeutics plc ADR (AUTL) with its peers suggests the former has fared considerably weaker in the market. AUTL showed an intraday change of -2.90% in last session, and over the past year, it shrunk by -64.74%%.
Data on historical trading for Autolus Therapeutics plc ADR (NASDAQ:AUTL) indicates that the trading volumes over the past 3 months, they’ve averaged 1.43 million. According to company’s latest data on outstanding shares, there are 266.12 million shares outstanding.
Nearly 9.70% of Autolus Therapeutics plc ADR’s shares belong to company insiders and institutional investors own 53.78% of the company’s shares. The stock has fallen by -14.47% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUTL stock heading into the next quarter.
